Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Economic Value Added (EVA)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Biogen Inc., economic profit calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2021 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial performance between 2017 and 2021 is characterized by a period of significant economic value growth that peaked in 2019, followed by a sharp contraction in profitability. Economic profit experienced a substantial decline in the final two years of the period, nearly erasing the gains achieved during the initial growth phase.

Net Operating Profit After Taxes (NOPAT)
NOPAT exhibited a strong upward trajectory from 2017 to 2019, increasing from US$ 2,890,089 thousand to a peak of US$ 6,023,385 thousand. This growth trend reversed in 2020, with profit falling to US$ 4,370,868 thousand, and culminated in a precipitous decline to US$ 1,501,467 thousand by 2021, indicating a severe erosion of operating profitability.
Invested Capital and Cost of Capital
Invested capital fluctuated over the period, peaking at US$ 14,142,400 thousand in 2019 before dipping in 2020 and rising again to US$ 13,824,500 thousand in 2021. Throughout this timeframe, the cost of capital showed a gradual and consistent downward trend, decreasing from 9.46% in 2017 to 8.61% in 2021. Although the lowering cost of capital reduced the financial hurdle for value creation, it was insufficient to offset the decline in operating earnings.
Economic Profit Analysis
Economic profit mirrored the trajectory of NOPAT, rising from US$ 1,709,844 thousand in 2017 to a peak of US$ 4,698,464 thousand in 2019. The subsequent downturn was stark; economic profit fell to US$ 3,259,282 thousand in 2020 and collapsed to US$ 311,206 thousand in 2021. This trajectory demonstrates a significant reduction in the ability to generate returns in excess of the cost of capital, signaling a transition from high value creation to near-breakeven economic performance by the end of 2021.


Net Operating Profit after Taxes (NOPAT)

Biogen Inc., NOPAT calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Net income attributable to Biogen Inc.
Deferred income tax expense (benefit)1
Increase (decrease) in reserves for allowances2
Increase (decrease) in restructuring reserve3
Increase (decrease) in equity equivalents4
Interest expense
Interest expense, operating lease liability5
Adjusted interest expense
Tax benefit of interest expense6
Adjusted interest expense, after taxes7
(Gain) loss on marketable securities
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income8
Investment income, after taxes9
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in reserves for allowances.

3 Addition of increase (decrease) in restructuring reserve.

4 Addition of increase (decrease) in equity equivalents to net income attributable to Biogen Inc..

5 2021 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

6 2021 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

7 Addition of after taxes interest expense to net income attributable to Biogen Inc..

8 2021 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

9 Elimination of after taxes investment income.


Net Income Attributable to Biogen Inc.
The net income exhibited a rising trend from 2017 to 2019, increasing from approximately 2.54 billion to nearly 5.89 billion US dollars. However, a decline was observed starting in 2020, with net income falling to about 4.00 billion and further decreasing sharply to approximately 1.56 billion US dollars in 2021. This indicates a significant reduction in profitability during the latter years of the period.
Net Operating Profit After Taxes (NOPAT)
The NOPAT followed a similar trajectory to net income, showing an increase from about 2.89 billion US dollars in 2017 to a peak of approximately 6.02 billion US dollars in 2019. Subsequently, a decline occurred with NOPAT decreasing to roughly 4.37 billion in 2020 and then sharply dropping to around 1.50 billion US dollars in 2021. This pattern signifies a reduction in operating efficiency and effectiveness in generating profit after taxes over the last two years.
Overall Observations
Both net income and NOPAT demonstrated growth during the initial three years, suggesting improved financial performance and operational results. The peak in 2019 represents the highest point in profitability within the analyzed period. The subsequent decline in 2020 and more pronounced drop in 2021 highlight challenges or adverse developments affecting profitability and operational outcomes. The data suggests the company experienced a notable downturn in earning capacity and operating profit in the final years.


Cash Operating Taxes

Biogen Inc., cash operating taxes calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Income tax expense
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


Income Tax Expense
The income tax expense demonstrates a consistent downward trend from 2017 to 2021. Starting at 2,458,700 thousand US dollars in 2017, the expense decreased significantly each year to reach 52,500 thousand US dollars in 2021. The reduction is particularly notable in 2021, where the expense dropped sharply compared to previous years.
Cash Operating Taxes
Cash operating taxes also show a general decline over the analyzed period. Beginning at 2,441,355 thousand US dollars in 2017, these taxes declined steadily year over year, falling to 533,599 thousand US dollars in 2021. The reduction is gradual until 2020, followed by a less steep but still notable decrease in 2021.
Comparative Analysis
Both income tax expense and cash operating taxes have followed a downward trajectory, reflecting a possible strategic or operational improvement affecting taxable income or tax planning. The income tax expense decreased more sharply between 2020 and 2021 compared to prior years, whereas cash operating taxes reduced more steadily across the entire timeframe.


Invested Capital

Biogen Inc., invested capital calculation (financing approach)

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Current portion of notes payable
Notes payable, excluding current portion
Operating lease liability1
Total reported debt & leases
Total Biogen Inc. shareholders’ equity
Net deferred tax (assets) liabilities2
Reserves for allowances3
Restructuring reserve4
Equity equivalents5
Accumulated other comprehensive (income) loss, net of tax6
Noncontrolling interests
Adjusted total Biogen Inc. shareholders’ equity
Construction in progress7
Marketable securities8
Invested capital

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of restructuring reserve.

5 Addition of equity equivalents to total Biogen Inc. shareholders’ equity.

6 Removal of accumulated other comprehensive income.

7 Subtraction of construction in progress.

8 Subtraction of marketable securities.


Total Reported Debt & Leases
The total reported debt and leases remained relatively stable from 2017 to 2019, with a slight decrease each year from approximately 6.45 billion US dollars to around 6.44 billion US dollars. However, there was a significant increase in 2020, rising to approximately 7.91 billion US dollars. In 2021, the debt slightly decreased to about 7.69 billion US dollars, indicating a reduction after the peak the previous year.
Total Biogen Inc. Shareholders’ Equity
Shareholders' equity showed a consistent upward trend from 2017 to 2019, growing from approximately 12.61 billion US dollars to 13.34 billion US dollars. In 2020, there was a notable decline to about 10.70 billion US dollars. This followed by a modest recovery in 2021, with equity increasing to approximately 10.90 billion US dollars, yet still below the peak levels observed in 2019.
Invested Capital
Invested capital experienced steady growth from 2017 through 2019, rising from approximately 12.48 billion US dollars to 14.14 billion US dollars. In 2020, invested capital dropped to about 12.63 billion US dollars but rebounded in 2021 to 13.82 billion US dollars. This pattern suggests some disruptions or adjustments during 2020, followed by partial recovery the following year.


Cost of Capital

Biogen Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Notes payable, including current portion3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in thousands

2 Equity. See details »

3 Notes payable, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Notes payable, including current portion3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in thousands

2 Equity. See details »

3 Notes payable, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Notes payable, including current portion3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2019-12-31).

1 US$ in thousands

2 Equity. See details »

3 Notes payable, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Notes payable, including current portion3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2018-12-31).

1 US$ in thousands

2 Equity. See details »

3 Notes payable, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Notes payable, including current portion3 ÷ = × × (1 – 35.00%) =
Operating lease liability4 ÷ = × × (1 – 35.00%) =
Total:

Based on: 10-K (reporting date: 2017-12-31).

1 US$ in thousands

2 Equity. See details »

3 Notes payable, including current portion. See details »

4 Operating lease liability. See details »



Economic Spread Ratio

Biogen Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Selected Financial Data (US$ in thousands)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2021 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The financial trajectory from 2017 to 2021 is characterized by an initial period of significant expansion in value creation followed by a severe contraction, particularly in the final year of the period.

Economic Profit Trends
Economic profit exhibited a strong upward trajectory from 2017 to 2019, increasing from US$ 1,709,844 thousand to a peak of US$ 4,698,464 thousand. This growth was followed by a moderate decline in 2020 to US$ 3,259,282 thousand and a precipitous drop in 2021 to US$ 311,206 thousand, representing a substantial reduction in the amount of value generated above the cost of capital.
Invested Capital Stability
Invested capital remained relatively stable throughout the analyzed period, oscillating between a low of US$ 12,476,129 thousand in 2017 and a peak of US$ 14,142,400 thousand in 2019. The consistency of the capital base suggests that the volatility in economic profit was driven by operational performance or changes in the cost of capital rather than significant fluctuations in the total investment employed.
Economic Spread Ratio Analysis
The economic spread ratio closely mirrored the trend of economic profit. A period of rapid efficiency gains occurred between 2017 and 2019, with the ratio climbing from 13.70% to 33.22%. However, this efficiency eroded in 2020 to 25.82% and collapsed to 2.25% by December 31, 2021. This sharp decline indicates that by the end of the period, the return on invested capital had converged with the cost of capital, nearly eliminating the capacity to create economic value.


Economic Profit Margin

Biogen Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Selected Financial Data (US$ in thousands)
Economic profit1
Revenue
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Economic profit. See details »

2 2021 Calculation
Economic profit margin = 100 × Economic profit ÷ Revenue
= 100 × ÷ =

3 Click competitor name to see calculations.


Between 2017 and 2021, a distinct cycle of expansion followed by a severe contraction in economic value creation is evident. Economic performance peaked in 2019, after which both revenue and economic profit experienced a significant downturn, culminating in a near-total erosion of the economic profit margin by 2021.

Economic Profit Margin Trends
The economic profit margin exhibited substantial growth in the early part of the period, rising from 13.93% in 2017 to a peak of 32.68% in 2019. This upward trajectory indicates a period of increasing efficiency in generating returns above the cost of capital. However, a reversal occurred in 2020, with the margin dropping to 24.24%, followed by a precipitous collapse to 2.83% in 2021.
Revenue and Economic Profit Correlation
Revenue growth mirrored the increase in economic profit from 2017 through 2019, with revenue climbing from 12.27 billion USD to 14.38 billion USD. While both metrics declined after 2019, the rate of decline for economic profit was significantly more aggressive. Between 2020 and 2021, revenue decreased by approximately 18.5%, whereas economic profit plummeted by roughly 90.4%, falling from 3.26 billion USD to 311.21 million USD.
Analysis of Value Creation
The sharp divergence between revenue decline and economic profit decline in 2021 suggests that the contraction was not merely a result of lower sales, but likely due to a significant increase in the cost of capital or a sharp rise in operating expenses relative to the invested capital base. The transition from a high-value creation phase in 2019 to a marginal state in 2021 indicates a critical reduction in the company's ability to create economic value for its stakeholders.